ARGX240920C490000
- 17.70
- 0.000.00%
argenx SE Newsroom
Here's Why Argenx SE (ARGX) Rose 9% in Q2
New Additions to Roth MKM's ADR Portfolio for September
Truist Financial Maintains Argenx SE(ARGX.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $argenx SE(ARGX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.4% and a total average return of 20.8% over the
Truist Financial Issues a Buy Rating on Argenx Se (ARGX)
This week's bullish stocks in the telecommunication sector! Vodafone, Telus, and AT&T have risen for 3 consecutive weeks; bullish news continues to materialize, with Tesla's weekly increase exceeding 7%.
Received a target price increase from a major bank! Coupang has risen over 5% this week and over 40% this year, with a market cap of over 40 billion USD.
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
Argenx to Present at Upcoming Investor Conferences
Evercore ISI Raises Price Target on Argenx to $555 From $533, Keeps Outperform Rating
JP Morgan Maintains Overweight on Argenx, Raises Price Target to $640
J.P. Morgan Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $640
J.P. Morgan analyst James Gordon maintains $argenx SE(ARGX.US)$ with a buy rating, and adjusts the target price from $500 to $640.According to TipRanks data, the analyst has a success rate of 56.3%
Express News | Argenx SE : JP Morgan Raises Target Price to $640 From $500
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading
Biotech Stocks: Which Drugmakers Are Worth a Buy?
10 Health Care Stocks With Whale Alerts In Today's Session
US stocks gold mining | Performance and stock price soar! The Trade Desk and Expedia surged more than 10% on Friday; cumulative gains exceeded 40% this year! Bio-pharmaceutical company argenx se's market cap has exceeded 30 billion US dollars.
Teaming up with Microsoft, software giant palantir's stock price has reached a new high this year, with a cumulative increase of nearly 75%.
Piper Lists Eight Defensive Biotechs to Face Market Volatility
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Barclays Upgrades Argenx to Overweight
Argenx Analyst Ratings